+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
89 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of secutrelvir for treating symptomatic nonhospitalized adults and adolescents with COVID-19 who are at high risk of developing severe disease. This phase 3 trial compares secutrelvir to a placebo to better understand its impact on preventing worsening illness and serious outcomes like hospitalization or death. Participants will be randomly assigned to receive either secutrelvir or a placebo. Both treatments are given orally as tablets. The study includes multiple assessments from baseline through 28 days, and safety monitoring continues up to 24 weeks after treatment. The trial is double-blind, so neither participants nor researchers know who receives the active drug or placebo. During the study, participants will be monitored for COVID-19 symptoms, viral levels, and health status through various measures such as symptom resolution times, medically attended visits, hospitalizations, and quality of life questionnaires. Blood samples will be collected on specific days to analyze drug levels and any side effects. The main outcome is to see how many participants experience worsening illness or serious events within 28 days of starting treatment.

Age: 12Years +All GendersPhase 3
51 locations
E

Actively Recruiting

Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.

Age: 12Years - 17YearsAll GendersPhase 3
30 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of berobenatide PF-08653944 in adults with obesity disease, a condition characterized by excess body fat that can harm health and increase the risk of other medical problems. Some participants may also have type 2 diabetes, where the body does not use insulin properly, leading to high blood sugar levels. This Phase 3 clinical trial is being conducted in Japan to better understand how berobenatide works for people with these conditions. Participants will be randomly assigned to receive either berobenatide or a placebo. Both treatments are given as injections under the skin of the abdomen once a week. The study compares the effects of berobenatide to placebo in helping people lose weight and examines its safety. About 180 adults will participate, and the study includes up to 15 in-person visits and 2 phone visits over approximately 22 months. During the study, participants will have their body weight and waist circumference measured, along with blood pressure and blood tests to check glucose, insulin, cholesterol, and inflammation markers. Questionnaires about quality of life related to weight will also be completed. Researchers will monitor for any side effects or adverse events. The main outcome is the percent change in body weight from the start to week 72, with other health measures also tracked throughout the trial.

Age: 18Years +All GendersPhase 3
34 locations

1-10 of 14

1